Q2 saw robust revenue and order intake growth, with improved EBITDA and a strengthened cash position. The order book is healthy, driven by MedTech demand, and management expects sustained profitability and growth, supported by new partnerships and a focus on AI and robotics.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.